Overview

Alirocumab in Patients With Sepsis

Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the drug alirocumab, which may lower cholesterol, can reduce the amount of inflammation caused by an infection that has caused either low blood pressure or difficulty breathing. Participants will be randomized to receive a single IV infusion of alirocumab or a placebo.
Phase:
Phase 1
Details
Lead Sponsor:
Jonathan Sevransky
Collaborator:
Regeneron Pharmaceuticals